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Abstract: Chronic hepatitis C1 is a common cause of liver disease worldwide. It is a slow and 
progressive condition which can lead to decompensated cirrhosis and hepatocellular carcinoma. 
Hepatitis C virus1 impairs quality of life (QOL) even in the absence of chronic liver disease, 
but its relative silent nature can lead to a delay in diagnosis. The current standard of care of 
treatment is pegylated interferon and ribavarin. This achieves a sustained virological response 
(SVR), which is a cure of infection, in up to 80% of patients depending on viral genotype. 
The attainment of SVR improves survival, avoids long-term complications, and improves 
QOL. But treatment is not only expensive; there are issues of tolerability and adverse effects. 
This has led to a multitude of cost effective analysis and health technology assessment on HCV 
treatment. This overview discusses the natural history of the virus infection and its effect on the 
patients’ QOL. It focuses on the treatment options available, their efficacy, and cost effective-
ness. It reviews the evaluations that suggest combination therapy is cost effective and explores 
the assumptions and limitations of these studies in real world treatment arenas.
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Introduction
The liver is the largest organ in the body and performs a host of functions including the 
processing and storage of nutrients and vitamins, degradation or elimination of metabolites, 
and the synthesis of plasma proteins including coagulation factors. Its ability to regenerate 
makes it unique and robust allowing it to survive various insults without sustained loss 
of function or capacity. Hepatitis C virus1-related viral hepatitis is one of the causes of 
hepatic injury resulting initially in inflammation, which if persistent and protracted, can 
cause fibrosis leading to cirrhosis. Hepatitis C infection is rapidly becoming one of the 
leading threats to public health internationally as a cause of current and future cirrhosis. 
National treatment plans are being developed, and it is vital given the size of this epidemic 
that these plans are based on robust evidence of cost-effectiveness.
Hepatitis C virus: the background
HCV is an enveloped, single-stranded RNA virus that causes acute or chronic infection. 
Transmission of the virus is parenteral in nature with needle sharing, unscreened blood 
transfusions, non-sterile tattooing or acupuncture, vertical and sexual transmission 
being among some of the means of viral exposure.
11 genotypes of the virus have been identified of which 6 predominate internation-
ally. There are clear differences in the distribution of the genotypes around the globe. 
Worldwide, genotypes 1–3 are most prevalent. Genotype 1a and 1b account for 60% ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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of all the infections globally. It is most prevalent in Europe, 
North America, and Japan. Genotypes 2 and 3 are seen in 
these countries less often and usually represent the   minority 
of infections. Genotype 3 is endemic in south-east Asia. 
Genotype 4 is principally found in the Middle East, Egypt, 
and central Africa. Genotype 5 is almost exclusively found 
in South Africa. Of the remaining, genotype 6 is the most 
prevalent and along with more minor genotypes numbered 
7–11 are seen in various countries in Asia.2
Within the UK, genotype 1 (G1) is most common, 
accounting for 40%–50% of infected cases, most commonly 
in those infected through blood products.3 The second largest 
group is genotypes 2 and 3, most commonly seen among drug 
users. In the UK, genotype 3 predominates over genotype 2. 
Genotypes 4–6 account for 5% of the infected subgroup and 
are more prevalent in other parts of the world.
Intravenous drug use remains the most common cause of 
HCV infection by a large margin and is the pre-eminent risk 
factor for future infection, with an estimated 50% prevalence 
of HCV infection among intravenous drug users.3,4 In many 
cohorts of patients, especially in developed countries, more than 
70% have acquired infection by this route. In approximately 
10%–40% of individuals the risk factor is never identified.
Globally, HCV infection affects 3% of the population 
with an estimated 170 million being chronic carriers.2 Within 
the UK, the estimated prevalence is approximately 185,000, 
about 0.5% of the population. In Scotland, approximately 
50,000 are estimated to be infected, with 37,500–39,000 of 
those infected chronically, nearly 1% of the population.4 Over 
three-fifths of those with chronic HCV infection in Scotland 
are male, with 88% of those diagnosed being under 50 years 
of age. This is very much in keeping with demographics 
internationally. Infection is thought to be more common in 
men for two reasons: men are more likely to inject drugs, and 
there are also men affected by hemophilia and more likely 
to have been infected with blood products.5
Acute infection is often asymptomatic and rarely results 
in hepatic failure. Of those infected, 70%–90% become 
chronic carriers of the virus.6 The natural history of chronic 
hepatitis is ill defined due to the long latent period between 
inoculum and development. Severity and progression is 
variable but generally slow.7
Complications of chronic hepatitis C (CHC) include cir-
rhosis, hepatocellular carcinoma and decompensated liver 
failure most commonly manifesting as ascites and varices. 
Studies have looked prospectively, retrospectively, and in 
nonconcurrent prospective ways at the natural history of 
hepatitis C. The differences between these approaches seem 
to show divergent outcomes, which have implications for the 
design of models of cost effectiveness.
The prospective studies looked mainly at the transfusion-
related NANB hepatitis and concluded that only 7%–15% 
developed cirrhosis and 1.3%–3.7% had liver-related death 
and even a smaller proportion progressed to HCC; however, 
follow-up on these studies, while long for prospective studies 
at between 15 and 25 years is short for the natural history of 
HCV .8–11 In addition, receiving a blood transfusion is not a 
benign intervention, and many patients will have succumbed 
to the underlying disease that necessitated the transfusion 
and will thus have not expressed the natural history of HCV . 
This is further exacerbated by the average age of transfusion 
recipients, which again precludes the expression of the full 
natural history of HCV . Therefore estimates of rates of pro-
gression to HCV disease endpoints in these studies should 
be regarded as the low end of the range. The retrospective 
studies used a variety of strategies to identify their base 
population; all are biased, as the patients have been diagnosed 
for some reason, often because they have presented with 
a complication of HCV disease or have been collected in 
referral centers. Unsurprisingly these were on the other end 
of the spectrum reporting a higher rate of cirrhosis, ranging 
from 17%–55% and liver-related mortality of up to 15.3%. 
The HCC incidence varied from 2%–23% depending on 
follow-up.12–15 The mixed retrospective   prospective studies 
are again limited by the biases discussed previously. These 
reported cirrhosis in 0.3%–5.9%16,17 but even higher at 15% 
in studies where follow-up was on men and longer than 40 
years with development of HCC seen in 1.9%.18 Liver-related 
mortality was reported between 1.0% and 2.1%.17
The differences reported in outcome and natural history 
is partly because of the groups studied and the methods 
employed to evaluate, as discussed above; although, host 
and environmental factors play a vital role in disease pro-
gression. Thus it is possible to view HCV natural history 
or progression as 3 groups; those that progress to cirrhosis 
within 20 years, those that progress over 20–50 years, and 
those that do not progress within their lifetimes. To which 
group an individual falls appears to depend more on host and 
environmental factors than purely viral factors. Invariable 
host factors that are associated with faster rates of fibrosis 
progression include advancing age, older age at infection, 
male gender, and high viral load.19 Genotype and ethnicity 
have not been firmly associated with disease progression but 
rather with reduced responsiveness to therapy, especially 
G1 and African Americans.20 The most significant variable 
associated with disease progression is alcohol consumption, ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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even at levels only moderately raised.21,22 The obesity-related 
metabolic syndrome and its complex relation with fibrosis 
are increasingly being recognized as a contributing factor to 
fibrosis progression.23 There is gathering evidence that use of 
cannabis and tobacco is also associated with fibrosis.
More patients are living longer with HIV infection than 
ever before, and a significant number are co-infected with 
HCV . Such individuals have a 2-fold increase in frequency 
and rate of development of cirrhosis; death from complica-
tions of liver disease now being one of the commonest causes 
of death among HIV-infected patients.24,25 These cofactors 
for progression have not been adjusted for in many models 
of disease progression. Once fibrosis is established and dec-
ompensation occurs, significant increases in morbidity and 
mortality result with only 51% surviving at 5 years compared 
with 91% of those with compensated cirrhosis.7,26 As a result 
of the disease process, HCV infection is now the most com-
mon cause of liver transplant within the   developed world.27
It is expected that the number of those with complications 
secondary to this condition will rise over the coming decades. 
Aside from the increased burden on health care, many of 
those infected are young and will have a significantly reduced 
  quality of life (QOL) without intervention.28   Consequently, 
there has been an increasing shift toward screening, 
  diagnosing, and treating people with this condition.
Treatment of hepatitis C
The aim behind all treatment options is to eradicate HCV 
viremia thereby increasing QOL and reducing the risk of cir-
rhosis and hepatocellular carcinoma. Non-pharmacological 
treatment includes counseling at diagnosis and the manage-
ment of non-specific symptoms such as fatigue. However 
pharmacological treatment is central as it can cure this 
chronic viral infection. Studies have confirmed and defined 
a surrogate marker for virlogical cure the absence of viral 
RNA in the patient’s blood 6 months after the cessation of 
therapy, and is termed sustained virological response (SVR). 
All patients with CHC should be considered for combina-
tion therapy except those with absolute contraindications 
to treatment.29–31 Though most individuals with active drug 
misuse are not considered for therapy as it is assumed that 
they have poor compliance and higher incidence of side 
effects and risk of subsequent reinfection.32
Interferons (pegylated and non-pegylated) are the main-
stay of treatment; they are normally used in conjunction 
with ribavarin. The mechanism of action is unclear but may 
include immune modulation at a cellular level as well as direct 
antiviral activity. Alpha interferon, both native and pegylated, 
result in flu-like symptoms,   hematological abnormalities 
including neutropenia, anemia, and   thrombocytopenia, 
and   neuropsychiatric disturbances like depression, fatigue 
and   suicidal ideation. Pegylated interferons have added 
  polyethylene glycol molecules to delay renal clearance mean-
ing the dose is delivered once weekly, which may have   positive 
implications relating to compliance. Ribavarin is a purine 
nucleoside analogue and can be given weight based or a flat 
dose. Its major side effect is hemolytic anemia which leads 
to dose reduction or stoppage of therapy in 9% of patients. 
Patients receiving a dose higher than 1 gm/d are at risk of 
hemolytic anemia.33 Though a degree of anemia produced as 
a side effect in patients has been shown to be associated with 
higher viral clearance. Success of treatment has been shown 
to be influenced by 3 major factors: HCV genotype, high 
pre-treatment viral load, and increased fibrosis. In general, 
genotypes 1 and 4 respond less well to treatment compared 
with other genotypes. In order to maximize the adherence 
to optimal treatment regimen hematopoietic growth factors 
have been used. Erythropoietin has been used in patients who 
develop anemia (,120 g/L) while on combination therapy 
(PEG interferon and ribavarin). It has been shown to improve 
anemia and consequently improve QOL.34,35 But to date it has 
yet to be demonstrated that this leads to an improvement in 
SVR or that this is cost effective.36
interferon monotherapy versus  
dual therapy
The story of treatment starts with interferon alpha, which 
was shown to be beneficial in 1986 though monotherapy 
of varying length had limited success. In the late 1990s, 
2 large randomized controlled trials assessed SVR comparing 
interferon monotherapy against the alternative of interferon 
plus ribavarin.37,38 Both trials demonstrated the superior-
ity of combination therapy over monotherapy resulting in 
a significantly increased SVR. Generally, the use of dual 
therapy improved SVR when used for 12 months rather than 
6 months, especially in patients with G1.
The results of these trials were further validated by 
meta-analyses of available studies, which reported SVR of 
32%–  41% with dual therapy compared with 8%  –16% with 
monotherapy.39 As a result, dual therapy became the treat-
ment of choice in CHC infection with clinical guidelines 
suggesting it be used in patients over 18 years of age with 
moderate to severe HCV infection for 6 months in treatment 
naïve patients with genotype 2 or 3 virus and 12 months in 
patients with G1 who have demonstrated a response by week 
24 of treatment.31ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Dual therapy with peginterferon versus interferon
The current standard of care is a combination of weekly 
  subcutaneous injection of long-acting pegylated interferon 
and daily oral ribavarin.29,30 There are two commercially 
available licensed pegylated interferons: peginterferon 
alpha-2a and peginterferon alfa-2b. They differ slightly in 
the interferon molecule by a few amino acids and in the 
size and nature of the covalently attached   polyethylene 
glycol (PEG) moiety, with resulting differences in 
  pharmacokinetics and in dosing regimens.40,41 Peginter-
feron alpha-2a has a very restricted volume of distribution, 
  longer half-life, and reduced clearance compared with 
native interferon alpha-2a, and can be given once weekly 
independently of bodyweight. Peginterferon alpha-2b has 
a shorter half-life in serum than peginterferon alpha-2a and 
requires bodyweight-based dosing.
Two double-blind randomized trials compared the efficacy 
of dual therapy with ribavarin and pegylated or non-pegylated 
interferon.42,43 In the first trial PEG + ribavirin was compared 
with interferon + ribavirin,43 and in the second trial both these 
options were compared with PEG monotherapy.43 It could be 
argued that the first trial is confounded as the benefits could 
be attributed to ribavirin, present in both treatment groups. 
However, ribavirin monotherapy has been shown to have 
little or no sustained virologic response. Furthermore, the 
results of the trial have since been externally validated by 
other studies.
At the end of 48 weeks treatment, both studies found a 
significant difference between dual therapies with PEG com-
pared with non-PEG interferon. This difference was main-
tained at the end of the follow-up period where 54%–56% of 
patients had a sustained response compared with 44%–47% 
in the non-PEG dual therapy arm. The results of these studies 
were pooled and analyzed according to response. Genotypes 
2 and 3 were identified as the most responsive to dual therapy, 
reaching SVR rates of 76%–82% at the end of follow-up.44 
Subsequent studies have shown that HCV genotypes 2 and 
3 can be treated with only 6 months of therapy with higher 
SVR.42 Davis also identified that virtually no patients with 
G1 went on to mount an SVR if at 12 weeks into dual therapy 
there was little or no reduction in the viral load. As a result 
of the data, it is now recommended that G1 patients with no 
early virologic response (EVR), defined as at least a two log 
drop in viral load, at 12 weeks should discontinue treatment. 
Patients with G1 who achieve EVR but are still HCV RNA 
positive should continue on treatment for 24 weeks. If PCR 
negative at this stage they should continue the full course of 
treatment; those positive should stop as they have no chance 
of an SVR. Those patients negative for HCV PCR at 12 
weeks should have a full 48 weeks treatment.30
Criteria for participant inclusion and exclusion were 
similar in these trials. All included patients were treatment 
naive with liver biopsy within the last year. The majority of 
included patients were male, in their 40s, with mainly G1 
and no significant co-morbidities. No explicit mention was 
made as to what proportion of the participants were drug 
users, former active or on opiate substitution therapy. It can 
be speculated that virtually no active substance users were 
included in the trials and that the proportions of former drug 
users in trials would be under represented. Most trials have 
excluded patients with co-infection with HIV , the rationale 
being that patients with a primary immune condition may not 
be able to mount a suitable response to result in successful and 
sustained virologic response.38,42,45 Additionally, progression 
of cirrhosis is increased by co-infection with HIV , which also 
makes viral clearance more difficult. The efficacy of therapy 
is reduced in this group, being dependent on the quality of 
HIV care and CD4 counts.46,47
Retrospective analysis of 4 studies considered the issues 
of compliance and adherence by dividing the participants into 
2 broad groups: those with .80% of the prescribed dose 80% 
of the time and those who were not as compliant. The study 
found that regardless of genotype, participants with high levels 
of adherence were more likely to have a sustained response at 
the end of follow-up. Most patients in the trials were adherent 
to their treatment regime over 80% of the time.48
Recently head to head studies between the two pegylated 
interferons have been reported, the largest being the IDEAL 
study reported no difference in SVR between the two drugs.49 
The meta analysis by Awad et al which is statistically under 
powered suggests “that peginterferon alpha-2a is associated 
with higher SVR than peginterferon alfa-2b. However, the 
paucity of evidence on adverse events curbs the decision to 
definitively recommend one peginterferon over the other 
because any potential benefit must outweigh the risk of 
harm”.50 The size of advantage was approximately a 10% 
increase in SVR, if this was born out in full analysis then it 
would have a limited impact on cost-effectiveness analysis 
but one financially significant given the size of the HCV 
epidemic facing many health care providers.
Quality of life issues
As many patients are asymptomatic, the health service 
burden due to HCV infection is initially minimal. This is 
altered once cirrhosis is established. Once symptoms occur 
they tend to be non-specific in nature with fatigue being the ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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most common symptom.51 Both patient and observer reported 
measures have been used to assess health-related quality of 
life ( HRQOL), disease impact, and mental health status 
in patients with CHC. One such tool is SF-36 which is a 
validated short form health survey. Patients with CHC show 
deficiency particularly in the physical and general health 
scales in SF-36 as compared with a normal population.52 
A limitation to this and other such tools is that measuring 
general health may fail to detect small but meaningful disease 
specific changes in QOL. Hence a Chronic Liver Disease 
Questionnaire(CLDQ) has been used to assess patients and 
is superior in measuring deterioration of QOL in patients 
with severe liver disease and CHC.53
There is an increasing body of evidence to show that 
QOL is reduced in HCV infection; however, manifesting 
symptoms are often nonspecific, or related to stigmatization, 
depression, and cognitive impairment.54
Studies objectively assessing QOL including vitality, 
ability to function socially, pain, and mood demonstrated 
reduced QOL measures in patients with hepatitis C similar 
to those in patients with Type 2 diabetes. Chronic hepatitis 
C carriers experienced more pain, less vitality, and reduced 
social functioning.55,56 One study confirmed reduced QOL 
measures among those with no history of drug use or chronic 
hepatitis infection; a subgroup that had previously been per-
ceived to have little or no impact to their lives as a result of 
diagnosis.28 Increasing evidence also suggests mild cognitive 
decline in those with mild CHC, which may also account for 
a decrease in QOL.57
Successful and sustained responses to treatment have 
been shown to improve life quality;55 this is further increased 
in those who receive dual therapy.52,58 Conversely, there is an 
increased emotional toll among those who are not selected 
for treatment with 71% of this group experiencing active 
psychiatric sequalae such as depression and psychosis, of 
whom 28%–40% may require treatment.59
Side effects of interferon therapy can be hard to tolerate. 
Injections can vary from once to thrice weekly depending on 
whether the pegylated or non-pegylated form is being used. 
Influenza-like symptoms are common after dosing. 50% 
of patients suffer non-specific symptoms such as fatigue, 
arthralgia, weakness, headaches, pyrexia, myalgia, nausea, 
and insomnia. A quarter of those treated are affected by hair 
loss, mood changes, pruritis, dermatitis, and rigors.60 Starting 
and maintaining treatment over the course of 6–12 months 
can result in substantial costs that are intangible and difficult 
to measure. Other costs that are not routinely considered in 
literature include indirect costs such as lost productivity.
Cost effectiveness of treatment  
of hepatitis C
Several studies have attempted to assess the costs related to 
hepatitis C. The full cost is sizeable predominantly because 
it is a condition that affects young adults. Due to the long 
latent period, many of the cost-effectiveness studies are based 
on hypothetical models that are updated when new data on 
clinical effectiveness is made available. As the standard of 
treatment is the use of pegylated interferon with ribavirin, 
this will remain the focus of this review of cost-effectiveness 
studies.
Bernfort et al considered cost effectiveness from the 
perspective of the Swedish health service in 200561 using 
data from the Manns43 study in a Markov model, which 
allowed simulation of a hypothetical cohort of patients with 
hepatitis C. The model was adapted to compare pegylated 
interferon (1.5 µg/kg/week) and ribavirin (800 mg daily) with 
interferon (3MIU 3/week) and ribavirin (100 mg–1200 mg 
daily). The model included not only SVR rates over a period 
of 20 years but also a stopping rule: those with no early 
viral response, defined as a reduction in viral load of 2 log 
units, were discontinued from treatment based on data from 
a study by Davis. Probabilities of transition from one health 
state to another over the defined time were based on studies 
on previous studies of Swedish patients with untreated HCV 
infection. Health states included cleared virus, moderate 
hepatitis, decompensated liver disease, hepatic encephalopa-
thy, hepatocellular carcinoma, and death. By the end of the 
model, all patients were dead. The QOL measures and the 
weighting given to each measure were derived or influenced 
from earlier studies.62,63 Cost data were from the Swedish 
health care system, were considered fixed, and therefore not 
included into sensitivity analysis. All prices were expressed 
in 2005 Euros. Cost-effectiveness analysis was estimated 
using incremental cost-effectiveness ratios (ICER). Results 
were presented separately according to genotype. While it is 
difficult to transfer studies from other countries to the UK, the 
discounted incremental costs per quality associated life years 
(QALY) are presented here (approximate 2005 exchange rate 
£1 = �1.461). For G1 patients, dual PEG + fixed ribavirin in 
comparison with dual IFN + ribavirin saved £140 with a 
gain of 0.29 QALYs, which makes PEG clearly dominant 
compared with interferon. For non-G1 patients, there are 
increased costs of £645 with a gain 0.09 QALY creating an 
incremental cost-effectiveness of £7,161/QUALY gained. 
Using an assumed willingness-to-pay (WTP), a cost of up to 
�40,000 (£27,397) for a QALY, the study demonstrated that 
PEG is cost effective even at very low WTP levels. Although ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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treatment with PEG is cost effective from a health system 
point of view, when looked at from the assumed societal 
perspective, the cost-effectiveness was reduced even at high 
WTP values. However, since the study considered no costs 
or benefits from a societal viewpoint, it is hard to assess how 
applicable this is in reality. The study concluded that while 
PEG is clearly indicated in patients with HCV-1 infection, 
it might not be as cost effective in HCV-2 or 3.
Siebert et al62 addressed the issue of cost effectiveness 
using data from the Manns43 study. Sustained virologic 
response rates were projected from each trial arm into a 
hypothetical Markov model. QOL measures were from a 
survey of German patients with CHC. Mulitvariate regres-
sional analysis was used to weigh each of the QOL measures. 
A panel of experts and a European QOL instrument was 
used to create the estimates used in the sensitivity analysis. 
Costs were from the German health care system and inflated 
and altered to match current rates. Cost effectiveness was 
measured in ICER with the perspective of society. Results 
were presented separately for fixed and weight-based dosing 
for ribavirin, as the trial identified a significant link between 
SVR and weight-based ribavirin dosing. Again, prices are 
presented here in Sterling (based on £1 = �1.95). Dual 
therapy with PEG and weight-based ribavirin in comparison 
with interferon and ribavirin had an incremental cost per 
QALY of £3,304. This increased to £6,051 per QALY when 
ribavirin dose was fixed, suggesting weight-based ribvirin 
dosing is more cost effective than fixed doses, assuming all 
patients respond well to doses related to their weight. Further 
sensitivity analysis demonstrated that these incremental cost-
utility values remained the best use of resources in clinical 
subgroups apart from those with genotype-2 HCV or high 
viral loads. It was speculated that this could be because of 
the high SVR achieved by the former of these groups and the 
low rates by the later irrespective of treatment.
Buti and colleagues64 reviewed not just effectiveness 
according to incremental cost but also benefits from the 
Spanish health system perspective. Patient characteristics 
and virologic response were obtained from Manns’ work. 
The focus was on response according to genotype, the effect 
of dosing according to weight, and the effects of   compliance 
with therapy. Costs came from the Spanish health care health 
system and did not consider production or indirect costs. The 
study investigators adjusted costs to current   values of the year 
2000. A discount rate of 3% was applied to future benefits 
and costs. Using similar models and data as the previous stud-
ies, the results provided external validation of the findings 
of Siebert and other cost-effectiveness   studies,   suggesting 
that the use of peginterferon for hepatitis C treatment was 
superior for all patients. Focusing on G1 HCV-infected 
patients, peginterferon and fixed-dose   ribavirin resulted in 
an incremental cost-effectiveness ratio of £1,750 per QALY 
gain. When ribavirin is adjusted to weight, this reduced the 
ICER to £1,732 and further dropped the cost to £277 per 
QUALY gain when patients were compliant with 80% of 
treatment over 80% of the treatment duration. The results 
demonstrated that the optimal treatment regime requires 
individual adjustment of ribavirin to patient weight and 
patient compliance. This increase in effectiveness is even 
more pronounced in the harder to treat patients with G1 
infection. The study did not look at the cost effectiveness of 
stopping therapy early if no viral response is achieved in the 
first 6 months of treatment.
Shepherd et al65 assessed cost effectiveness of peginter-
feron and ribavarin in 2005. They used a similar hypothetical 
model to simulate the outcomes of a cohort of HCV patients. 
Unlike previous models, the age of diagnosis was younger 
at 36 years rather than 43. Disease progression in the model 
was based on rates in literature with SVR rates being based 
on a meta-analysis of two large randomized controlled 
trials,43,44 while subgroup analysis was based on the study by 
Davis. Values relating to utility were taken from literature 
or estimated by a panel of experts using a standardized QOL 
scale. Costs were direct but excluded capital and overhead 
costs. Market value drug costs were summarized from the 
national formulary. Variations in SVR, discounting for both 
benefits and cost, and drug costs were addressed in a sen-
sitivity analysis. As in previous studies, Shepherd and his 
colleagues confirmed the cost effectiveness of peginterferon 
and ribavirin over interferon alone at a cost of £12,123/QALY 
gained. Predictably, the incremental cost-effectiveness ratio 
was increased in patients with a high viral load irrespective 
of genotype. When grading cost effectiveness by sustained 
response according to genotype, it was clear that HCV-2 
and -3 patients had the better estimates based on the out-
comes of one study (£7,051/QUALY saved) compared with 
the higher cost of HCV-1 patients at £10,848. When SVR 
rates from the Manns study were used, the costs for HCV-2 
and -3 treatment rose to £37,578/QUALY gain. The authors 
speculated that this might have been due to the marginal 
difference between the SVR rates of those treated with PEG 
versus interferon (82% and 79% respectively). This increase 
might be because of the increased response to treatment rate 
in this genotype subgroup. Even with variations of costs, 
discount, and SVR, the cost per QALY remained under 
£30,000, making PEG the most clinically and cost-effective ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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pharmacological option. Additionally, the authors showed 
clearly that stopping treatment after 12 weeks in HCV-1 
patients with no early virologic response could result in sub-
stantial cost savings of approximately 16%. Were treatment 
to continue after the 12-week point in non-responders, the 
continuing cost of treatment would be £226,573 per QALY 
compared with the alternative of no treatment.
Several studies have assessed the cost effectiveness of 
peginterferon and ribavirin versus interferon and ribavirin 
therapy using hypothetical models to predict cost-utility 
ratios. Overall, the studies show dual treatment with pegy-
lated interferon is superior to the use of interferon dual 
therapy, both clinically and cost-benefit wise. Results also 
demonstrate that genotypes 2 and 3 had lower ICER within 
subgroup analysis compared with G1 patients. Stopping treat-
ment in patients with no early virologic response could save 
the health system a substantial amount in terms of cost and 
would also prevent further unnecessary side effects among 
this patient group.
Cost effectiveness in real  
world settings
In the main, the models described above have made realistic 
assumptions on the natural history of HCV infection and 
have used the best treatment outcome data available from 
the large randomized controlled trials. However these trials 
under represent key subgroups of patients for treatment: most 
significantly those on opiate substitution therapy and those 
who have recently given up intravenous drug use, which many 
authorities now regard as suitable for therapy. The cohort of 
patients being treated in many centers is primarily made up 
of people with concurrent issues such as drug abuse, but also 
including worries about accommodation, transport costs, and 
social care issues. Motivation for treatment is often reduced, 
as HCV infection is one of many life issues they have to face 
and is the one that is least pressing in the short term. This will 
clearly have an impact on compliance with therapy, which 
as has been shown above is a key determinant to achieving 
SVR. Little comment is passed regarding the number of 
included participants who are on a substance misuse stabi-
lization program in the controlled trials that so many of the 
cost-effectiveness studies are extrapolated from. Sheerin and 
colleagues66 are one of the very few groups to have addressed 
this issue. The focus of their model was to consider how cost 
effective it is to treat IDU patients with HCV on a mainte-
nance program, address issues regarding the implications of 
making treatment available to all IDU patients who meet the 
criteria and consider the effects on cost effectiveness if the 
age of stabilization of drug therapy lowered and also to assess 
the variation of cost effectiveness among Maori subgroups. 
The analysis compared dual interferon and ribavirin therapy 
with no antiviral therapy in New Zealand. A Markov model 
was constructed and adapted to include a higher dropout 
rate of 50%2 compared with that of 20%–30% in the studies 
of Manns43 and Fried.42 Assumptions for the model came 
from data in which the community acquired rate of progres-
sion to chronic hepatitis C is an estimated 8%, much less 
than the 20% used in other models. The model simulated a 
chronic relapsing pattern before stabilization of the patient 
on methadone replacement at the age of approximately 31 
years of age. Costs included treatment of drug abuse and 
hepatitis C. The costs for methadone replacement therapy 
were taken from previous costs within New Zealand. The 
cost of non-pegylated interferon plus ribavirin therapy was 
taken from Australian counterparts, as it was not offered 
under the New Zealand health system, with the assumed 
cost of pegylated interferon being set at 20% higher than 
its non-pegylated alternative. These costs were direct, in 
keeping with assessment from a health institution point of 
view. Sensitivity analysis varied rates of progression of the 
disease. Benefits were recorded in life years, and data were 
presented in terms of incremental costs per life year gained. 
No QOL analysis was performed. Overall, both interferon 
and peginterferon remained cost effective compared with no 
treatment. Incremental cost-effectiveness ratios, measured in 
cost per life year gain, were favorable compared with no treat-
ment. This was very much the case in non-Maori subgroups. 
The study also found that reducing the age of stabilization 
from the average of 31 to 26 years of age would be even 
more cost effective.
Much of the data upon which the cost-effectiveness 
analyses are based assumes compliance, and this is to be 
expected to some degree within the supported environment 
of controlled trials. We can speculate that the participants 
in the trials were likely to be highly motivated and adher-
ent to treatment courses, and yet even with this assumption 
20%–30% of participants failed to complete the course of 
treatment due to adverse effects. While Sheerin and col-
leagues66 demonstrated that patients who were stabilized 
on substance misuse therapy and also managed for HCV 
remained a cost-effective option, it is unclear how many of 
this vulnerable group are even referred or enrolled for treat-
ment. Initial reports of case series of treatment outcomes 
showed much lower rates of SVR were achieved compared 
with clinical trials. However, more recent reports show rates 
comparable to and exceeding those seen in clinical trials, ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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particularly with the most recent cohorts.67 This appears to 
be due to the evolution of better pathways of care, offering 
patient support to adhere to therapy, and more conservative 
therapy reductions to deal with side effects. The additional 
costs of these supports need to be factored into the analysis 
especially of some of these more difficult to treat patient 
groups, but this is likely to be balanced with much lower 
dropout rates than were modeled in the analysis. Another 
factor that needs to be considered when interpreting these 
analyses is the assumption of normal survival post SVR. 
Hopefully this is a valid assumption for most patients; it is 
less certain for those who are already cirrhotic, although 
undoubtedly better than if they had ongoing infection. The 
survival of patients on methadone treatment programs for 
opiate dependence is reduced,68 and this will reduce the cost 
effectiveness of anti-HCV treatment in this patient group, 
as it will reduce their post cure survival.
Future developments
There are two major developments occurring in the 
field of HCV therapy that are yet to undergo detailed 
cost-effectiveness analysis: reduced treatment courses guided 
by patient response and the development of new drugs. The 
reduced treatment courses are already approved for patients 
with G1, with low viral loads, who become HCV PCR nega-
tive after 4 weeks of therapy, a rapid virological response 
(RVR). In these patients, treatment can be reduced from 48 
weeks to 24 weeks. Patients in this group have high SVR 
rates, greater than 80%.69 This subgroup of patients represents 
about 25%–30% of most G1 cohorts in European countries. 
It does not require formal analysis to conclude that this will 
enhance the cost effectiveness of therapy. Similar reduced 
duration regimes based on an RVR are being developed for 
genotypes 2 and 3. Optimal duration of therapy is yet to be 
fully defined but ranges between 12 and 16 weeks.70
There are a significant number of new therapies for 
HCV in development. Most of these are protease inhibitors 
directed against G1 virus. Other classes of drug are also 
being developed but are not so close to licensing. Two new 
protease inhibitors are likely to be licensed for use in 2011 
or soon after: telaprivir and boceprivir.71,72 These two drugs 
are both used for part of the treatment period and increase 
SVR in both treatment naïve and experienced patients. They 
may also reduce treatment duration. There is no indica-
tion of the cost of these products, but they are likely to be 
expensive and will require careful evaluation of their cost 
effectiveness. If they are priced too high, it may be more cost 
effective to treat patients with good predictors of response 
to therapy with   current standard of care and reserve the new 
drugs for   treatment failures and those with poor predictors 
of response.
Conclusions
It can be concluded that dual therapy with pegylated inter-
feron and ribavirin remains the treatment of choice for HCV 
infection, and this choice is cost effective for use in most 
health care systems. The use of patient-specific early viral 
responses will prevent further adverse effects of contin-
ued treatment with little or no added benefit to the patient 
population and also allow shortened therapy for some with 
no adverse effect on outcome. The key to maintaining the 
cost effectiveness of therapy is the SVR rate. If this falls too 
far from those rates seen in the RCT’s used to inform the 
cost-effectiveness models, then the therapy may no longer 
be cost effective. The use of adjuncts to treatment, like 
hematopoietic growth factors, may improve patient adher-
ence with treatment and QOL, but have yet to be shown to 
improve SVR; and unless the size of this improvement is 
large they are unlikely to be cost effective in most health 
care settings. The costs of bringing patients from more 
difficult to treat backgrounds into therapy and maintaining 
them in treatment have up until now not been addressed 
in any cost-effectiveness analysis, and as the treatment 
population is increasingly dominated by this group, further 
analysis will be needed to take this into account. While there 
is no clear evidence that starting HCV treatment will cause 
people from an IVDU background to change health behavior 
and enter or stabilize on an opiate substitution program, it 
is another health benefit that early reports are suggesting 
might be relevant and if substantiated would increase the 
cost effectiveness of therapy in this group. There is clear 
evidence that treatment of HCV is cost effective, but this is 
a complex and rapidly evolving treatment area and much of 
the analysis reviewed will quickly be outdated by application 
of treatment to different disease populations and the arrival 
of new drugs.
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